A group of doctors are urging researchers to look at psychedelics to ease the often overwhelming distress faced by women with late-stage gynaecological cancers.
Research and drug development company Albert Labs has announced it will begin trading on the CSE.
A new collaboration will investigate the efficacy of EVM-101, a first-generation psychedelic treatment, for the treatment of Cancer Related Distress (CRD).
New data from the Aquilino Cancer Center Study has shown the safety and feasibility of psilocybin therapy for the treatment of depression in cancer patients.